Structure Therapeutics’ Post

M&As are making waves. 🌊 If you're caught in middle, now is the time to explore new partnerships. As a nimble CDMO, American Injectables offers immediate capacity and long-term collaboration. Exploring your options? Let's talk. https://hubs.li/Q02JD6lX0 #CDMO #Partnership #PharmaceuticalManufacturing #SterileInjectables #SupplyChainResilience

With a looming patent cliff that puts about 90% of $BMY total revenues at risk of losing exclusivity by 2028, the pharma will need to execute a string of clinical and commercial successes to avoid a painful transition period

Microbot Medical (NASDAQ: MBOT) Receives FDA Nod for Human Clinical Trial, Stock Surges https://lnkd.in/d9qqMgu7 $MBOT #Nasdaq #stocks #stockmarket #stockmarketnews #BusinessNews #news #NewsAlert

Sidley successfully led the Chapter 11 cases for Impel Pharmaceuticals and one of its subsidiaries — culminating with the confirmation of their liquidation plan in the Bankruptcy Court for the Northern District of Texas. The Sidley team was led by Sam Newman, Rakhee Patel, and Jackson Garvey, and included Stephen Hessler, Nate Elner, Parker Embry, Chelsea McManus, and Andreas Rauch. Read more below. #restructuring #Chapter11

In September 2019, Purdue Pharma L.P., one of the largest pharmaceutical companies in the United States, filed for bankruptcy protection in the United States Bankruptcy Court for the Southern District of New York. The bankruptcy was filed to stem the tide of litigation Purdue faced as a result of its alleged role in the opioid crisis. The high profile nature of the filing generated enormous backlash from the public and the media. Proposed legislation was introduced in both Congress and the Senate to curb what was perceived as an attempt by the Sackler family (which owned Purdue Pharma) at 'gaming' the system. My next series explores this case in depth. We start with the Bankruptcy Court ruling and track the appeals which ultimately wound up before the United States Supreme Court. Part 1 is below:

According to BioWorld News, January biopharma deals exceed $26B, marking sixth-highest month Biopharma deals in January reached $26.97 billion, marking the sixth-highest month in BioWorld’s records going back to 2016. It is an increase of nearly 25% from the $21.64 billion in deals in January 2023 and also is up from December. Value the first month of the year is more than 2023’s average monthly value of $18.14 billion, and likewise more than the average monthly value of any previous year. While M&As are up 132.61% from January 2023’s $2.8 billion, the $6.52 billion value in the first month of 2024 falls short of December 2023’s $52.02 billion and the 2023 average of $11.65 billion per month.

Dealmaking is picking up... Following a downturn in M&A activity during 2022 and 2023, the biopharma industry is increasing its level of dealmaking. Dive in: https://ow.ly/rPZJ30sCOX8

Have you ever wondered why Capital Rx favors using #NADAC pricing over Average Wholesale Price (#AWP)? In another of our #BestOf2023 blogs, Josh Golden broke down the rationale for using an acquisition cost-based index, including: 📈 How AWP paved the way for contractual games 🔎 Why NADAC's public accessibility and price stability make it a great option for #PBMs and plan sponsors ✅ Why Capital Rx uses NADAC instead of AWP Read the blog below! #drugprices #PharmacyBenefitAdministration #pharmacybenefits #transparency https://okt.to/qjSfW5

BcFG is coming closer to reality everyday. 1. Land purchase is nearing completion -> will start building. 2. CDMO of interest identified for particular drug formulations and administration routes. 3. Potential venture capitol investors communicating with. 4. Business is set to become a reality once Land purchase is closed. 5. Trademark and copyright will be next. 6. Licensing of the patent to BcFG from myself. 7. Finalization of venture capitol and CDMO partners. 8. Clinical trials 9. FDA approval 10. Market - We will also be selling antiseptics without FDA approval meant for surface disinfection.(but if you chose to use them on yourself could work as a topical, but would be strongly discouraged) #BcFG #antibiotics #antiseptics #business #venturecapitol #venture #money #funding #invest #investment #changetheworld #licensing #clinicaltrials #drugs #steps #stepbystep #makingprogress #alwaysprogressing

Hold that Terminal Disclaimer! The same Federal Circuit panel who took away patent term adjustment (PTA) in Cellect has given it back for "first-filed, first-issued" patents--or at least shielded them from obviousness-type double patenting (OTDP) rejections over later-filed, later-issued patents that have the same priority date. This ruling preserves the ability to benefit from the "congressionally guaranteed patent term" associated with PTA in a "first" patent, and is good news for patent owners. Just make sure you've had your coffee before you try to follow how the opinion reconciles its holding with Cellect, Gilead, and other recent OTDP decisions. #patents #pharmapatents #patentlitigation